Lundbeck的CGRP单抗Vyepti用于预防偏头痛,获得美国批准

2020-02-25 不详 MedSci原创

Lundbeck的CGRP抑制剂Vyepti(eptinezumab)获得FDA批准上市,用于预防成人偏头痛。该药物的上市意味着成为进入美国市场的第四种CGRP单抗药物。

Lundbeck的CGRP抑制剂Vyepti(eptinezumab)获得FDA批准上市,用于预防成人偏头痛。该药物的上市意味着成为进入美国市场的第四种CGRP单抗药物。

但是Vyepti是第一个也是唯一的静脉内使用的CGRP抗体,因为目前另外三种药物Amgen / Novartis的Aimovig(erenumab),Teva的Ajovy(fremanezumab)和Eli Lilly的Emgality(galcanezumab)均使用皮下注射。

乍看之下,静脉输液似乎是一个劣势,但Lundbeck指出Vyepti只需要每三个月进行一次给药,而其竞争对手则需要每月注射一次。此外,静脉内给药意味着Vyepti的起效更快。

Lundbeck首席执行官Deborah Dunsire表示:"我们现在提供了一种新的静脉注射的CGRP抑制剂,该疗法达到了预防偏头痛的关键治疗目标,同时也满足了早期起效的需要。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2055049, encodeId=b875205504923, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Apr 11 17:19:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820080, encodeId=7ff2182008001, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Fri Feb 05 12:19:00 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734642, encodeId=97d71e346424e, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Sun Apr 19 06:19:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951938, encodeId=0948195193828, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Jan 14 13:19:00 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631105, encodeId=9b24163110587, content=<a href='/topic/show?id=404611100b1' target=_blank style='color:#2F92EE;'>#Lundbeck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11100, encryptionId=404611100b1, topicName=Lundbeck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fa921680613, createdName=fzwish20007, createdTime=Thu Feb 27 08:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2055049, encodeId=b875205504923, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Apr 11 17:19:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820080, encodeId=7ff2182008001, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Fri Feb 05 12:19:00 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734642, encodeId=97d71e346424e, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Sun Apr 19 06:19:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951938, encodeId=0948195193828, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Jan 14 13:19:00 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631105, encodeId=9b24163110587, content=<a href='/topic/show?id=404611100b1' target=_blank style='color:#2F92EE;'>#Lundbeck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11100, encryptionId=404611100b1, topicName=Lundbeck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fa921680613, createdName=fzwish20007, createdTime=Thu Feb 27 08:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2055049, encodeId=b875205504923, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Apr 11 17:19:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820080, encodeId=7ff2182008001, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Fri Feb 05 12:19:00 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734642, encodeId=97d71e346424e, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Sun Apr 19 06:19:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951938, encodeId=0948195193828, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Jan 14 13:19:00 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631105, encodeId=9b24163110587, content=<a href='/topic/show?id=404611100b1' target=_blank style='color:#2F92EE;'>#Lundbeck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11100, encryptionId=404611100b1, topicName=Lundbeck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fa921680613, createdName=fzwish20007, createdTime=Thu Feb 27 08:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2055049, encodeId=b875205504923, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Apr 11 17:19:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820080, encodeId=7ff2182008001, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Fri Feb 05 12:19:00 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734642, encodeId=97d71e346424e, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Sun Apr 19 06:19:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951938, encodeId=0948195193828, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Jan 14 13:19:00 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631105, encodeId=9b24163110587, content=<a href='/topic/show?id=404611100b1' target=_blank style='color:#2F92EE;'>#Lundbeck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11100, encryptionId=404611100b1, topicName=Lundbeck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fa921680613, createdName=fzwish20007, createdTime=Thu Feb 27 08:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2021-01-14 gostraight
  5. [GetPortalCommentsPageByObjectIdResponse(id=2055049, encodeId=b875205504923, content=<a href='/topic/show?id=fa0ee98149c' target=_blank style='color:#2F92EE;'>#美国批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79814, encryptionId=fa0ee98149c, topicName=美国批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Sat Apr 11 17:19:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820080, encodeId=7ff2182008001, content=<a href='/topic/show?id=fa3a10028630' target=_blank style='color:#2F92EE;'>#预防偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100286, encryptionId=fa3a10028630, topicName=预防偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Fri Feb 05 12:19:00 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734642, encodeId=97d71e346424e, content=<a href='/topic/show?id=83664555be' target=_blank style='color:#2F92EE;'>#CGRP单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4555, encryptionId=83664555be, topicName=CGRP单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93b333794310, createdName=zll0636, createdTime=Sun Apr 19 06:19:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951938, encodeId=0948195193828, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Jan 14 13:19:00 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631105, encodeId=9b24163110587, content=<a href='/topic/show?id=404611100b1' target=_blank style='color:#2F92EE;'>#Lundbeck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11100, encryptionId=404611100b1, topicName=Lundbeck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fa921680613, createdName=fzwish20007, createdTime=Thu Feb 27 08:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]

相关资讯

大冢及Lundbeck长效版Abilify新药申请审批遭FDA推迟

FDA已推迟了长效版(每月一次)重磅抗精神病药物Abilify的新药审批申请。大冢(Otsuka)制药及合作者Lundbeck,今天公布了FDA回复给公司的完整回应函(CRL),称FDA在最近的检查中发现为生产该药提供无菌水的第三方供应商存在缺陷。 "大冢正在与第三方供应商共同努力,尽早解决这一问题,并计划与FDA进行进一步的讨论以决定下一步骤,"大冢在今天的一份声明中说道。Abilify为年销

Lundbeck以近20亿美元收购Alder BioPharmaceuticals,获得CGRP抑制剂eptinezumab的权利

Lundbeck表示,将以每股18.00美元的现金,总价值高达19.5亿美元收购Alder BioPharmaceuticals公司,以获得其两项预防偏头痛实验性疗法的权利,包括CGRP抑制剂eptinezumab和PACAP抑制剂ALD1910。

Lundbeck制药的帕金森新疗法

H. Lundbeck A / S(Lundbeck)再次扩大了其临床开发项目的管线,并启动了一项关于帕金森病潜在新疗法的I期研究。该化合物为Lu AF28996,由Lundbeck发明,现在将作为其临床开发的第一部分在健康志愿者中进行研究。